Literature DB >> 2661335

Monoclonal antibodies in detection of choroidal melanoma.

P J Ringens1, R van Haperen, C Vennegoor, P T de Jong, S G van Duinen, D J Ruiter, A W van der Kamp.   

Abstract

Three monoclonal antibodies (MoAbs) prepared against cutaneous melanomas were tested against one group of 12 choroidal melanomas with indirect immunofluorescence in frozen sections. A fourth MoAb was tested in paraffin sections of a second group of 47 choroidal melanomas. One MoAb (NKI-M7) did not react with choroidal melanoma, even though it had a high sensitivity for cutaneous melanoma. A second MoAb (NKI-M6) showed a positive reaction with only 2/12 choroidal melanomas. The third MoAb (NKI/beteb) reacted with all choroidal melanomas, regardless of the cell type. MoAb NKI/C-3 was positive with 38/47 (81%) choroidal melanomas. We conclude that NKI/C-3 and NKI/beteb have a high sensitivity for both cutaneous and choroidal melanomas in frozen sections. Of these two antibodies NKI/beteb was the most specific for cutaneous naevi and melanomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2661335     DOI: 10.1007/bf02172764

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  23 in total

1.  Skin tests with soluble melanoma antigens in patients with choroidal tumors.

Authors:  D H Char; A Hollinshead; R B Herberman
Journal:  Cancer       Date:  1977-10       Impact factor: 6.860

2.  An antimelanoma monoclonal antibody and the histopathology of uveal melanomas.

Authors:  R Folberg; L A Donoso; B F Atkinson; C S Ernst; M Herlyn; V V Arbizo
Journal:  Arch Ophthalmol       Date:  1985-02

3.  Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells.

Authors:  J E de Vries; G D Keizer; A A te Velde; A Voordouw; D Ruiter; P Rümke; H Spits; C G Figdor
Journal:  Int J Cancer       Date:  1986-10-15       Impact factor: 7.396

4.  Soluble membrane antigens of human malignant melanoma cells.

Authors:  A C Hollinshead; R B Herberman; W J Jaffurs; L K Alpert; J P Minton; J E Harris
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

5.  Monoclonal antibodies in ophthalmology.

Authors:  M M Rodrigues
Journal:  Am J Ophthalmol       Date:  1985-06-15       Impact factor: 5.258

6.  A comparison of some methods for identifying amelanotic and oligomelanotic melanoma metastases in paraffin sections.

Authors:  A A Palmer; B E Hall; M Lew
Journal:  Pathology       Date:  1985-04       Impact factor: 5.306

7.  Decreased expression of HLA class II antigens on human uveal melanoma cells after in vivo X-ray irradiation.

Authors:  M J Jager; J P van der Pol; D de Wolff-Rouendaal; P T de Jong; D J Ruiter
Journal:  Am J Ophthalmol       Date:  1988-01-15       Impact factor: 5.258

8.  S-100 protein as a marker for melanocytic and other tumours.

Authors:  A J Cochran; D R Wen
Journal:  Pathology       Date:  1985-04       Impact factor: 5.306

9.  [Value of serologic tumor tests in malignant melanoma of the choroid].

Authors:  B Dieckhues
Journal:  Klin Monbl Augenheilkd       Date:  1986-02       Impact factor: 0.700

10.  Assessment of immunological techniques in the diagnosis and prognosis of ocular malignant melanoma.

Authors:  A J Cochran; W S Foulds; B E Damato; G E Trope; L Morrison; W R Lee
Journal:  Br J Ophthalmol       Date:  1985-03       Impact factor: 4.638

View more
  2 in total

1.  Radioimmunoscintigraphy and immunohistochemistry with melanoma-associated monoclonal antibodies in choroidal melanoma: a comparison of the clinical and immunohistochemical results.

Authors:  D F Schaling; J P van der Pol; M J Jager; M J van Kroonenburgh; J A Oosterhuis; D J Ruiter
Journal:  Br J Ophthalmol       Date:  1990-09       Impact factor: 4.638

2.  High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma.

Authors:  T J de Vries; D Trancikova; D J Ruiter; G N van Muijen
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.